Sulková S, Kvasnicka J, Kasl M, Kozlová J, Podrouzek P, Bartůnková J, Válek A
Cas Lek Cesk. 1989 Sep 29;128(40):1257-60.
Five women aged 50-64 years with chronic renal failure, due to interstitial nephritis, enlisted in a regular dialyzation programme were treated for three months with human recombinant erythropoietin. The blood haemoglobin level rose from 78.0 +/- 6.9 g/l to 108.4 +/- 15.5 g/l, the haematocrit from 21.8 +/- 1.8% to 33.6 +/- 4.9%. The serum ferritin concentration declined from 2213 +/- 1892 micrograms/l to 850 +/- 953 micrograms/l. Contrary to the period before treatment, during erythropoietin administration no blood transfusion had to be administered. The general condition of the patients improved. There were no serious complications. The action of erythropoietin persisted for two months. Human recombinant erythropoietin is significant help in the treatment of patients with chronic renal failure.
5名年龄在50 - 64岁之间、因间质性肾炎导致慢性肾衰竭且参加常规透析项目的女性，接受了3个月的重组人促红细胞生成素治疗。血红蛋白水平从78.0±6.9g/L升至108.4±15.5g/L，血细胞比容从21.8±1.8%升至33.6±4.9%。血清铁蛋白浓度从2213±1892μg/L降至850±953μg/L。与治疗前阶段相反，在促红细胞生成素给药期间无需输血。患者的一般状况有所改善。未出现严重并发症。促红细胞生成素的作用持续了两个月。重组人促红细胞生成素对慢性肾衰竭患者的治疗有显著帮助。
